A Comparison of Inducible Gene Expression Platforms: Implications for Recombinant Adeno-Associated Virus (rAAV) Vector-Mediated Ocular Gene Therapy
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The ability to temporally control levels of a therapeutic protein in vivo is vital for the development of safe and efficacious gene therapy treatments for autosomal dominant or complex retinal diseases, where uncontrolled transgene overexpression may lead to deleterious off-target effects and accelerated disease progression. While numerous platforms exist that allow for modulation of gene expression levels - ranging from inducible promoters to destabilizing domains - many have drawbacks that make them less than ideal for use in recombinant adeno-associated virus (rAAV) vectors, which over the past two decades have become the mainstay technology for mediating gene delivery to the retina. Herein, we discuss the advantages and disadvantages of three major gene expression platforms with regard to their suitability for ocular gene therapy applications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Riboswitches have gained considerable attention for rAAV ocular therapies because of their small size (100 bp cis-acting RNA sequence), adaptability to ligands, and the development of synthetic riboswitches [173,178,179].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [173]
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S., & Yang, S.-H. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.37 · Cited by 1,273
Banaszynski, L. A., Chen, L.-C., Maynard-Smith, L. A., Ooi, A. G. L., & Wandless, T. J. (2006) · Cell · doi:10.1016/j.cell.2006.07.025 · Cited by 902
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
Small-Molecule Binding Aptamers: Selection Strategies, Characterization, and Applications
Ruscito, A., & DeRosa, M. C. (2016) · Frontiers in Chemistry · doi:10.3389/fchem.2016.00014 · Cited by 391
A General Chemical Method to Regulate Protein Stability in the Mammalian Central Nervous System
Iwamoto, M., Björklund, T., Lundberg, C., Kirik, D., & Wandless, T. J. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.07.009 · Cited by 386
Shockett, P., Difilippantonio, M., Hellman, N., & Schatz, D. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6522 · Cited by 378
A comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
Riboswitch-Mediated Gene Regulation: Novel RNA Architectures Dictate Gene Expression Responses
Sherwood, A. V., & Henkin, T. M. (2016) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104306 · Cited by 215
Technique of retinal gene therapy: delivery of viral vector into the subretinal space
Xue, K., Groppe, M., Salvetti, A. P., & MacLaren, R. E. (2017) · Eye · doi:10.1038/eye.2017.158 · Cited by 191
Cited by
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“Riboswitches ~100 ligand-sensing aptamer, a communication module (linker), and an effector domain (ribozyme) [173,178,179]”
BackgroundCRISPRa‐based activation of Fgf21 and Fndc5 ameliorates obesity by promoting adipocytes browning
Zhu, H., Liu, D., Sui, M., Zhou, M., Wang, B., Qi, Q., Wang, T., Zhang, G., Wan, F., & Zhang, B. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1326 · Cited by 28
In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges
Cantore, A., Fraldi, A., Meneghini, V., & Gritti, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.774618 · Cited by 17
Characteristics, Recombination Methods, and Applications Progresses of Split-Cas9 System
Liu, Z., Huang, L., Deng, H., Chen, Y., & Xiao, H. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.223 · Cited by 5
Mechanisms and Research Methods of Protein Modification in Virus Entry
Xiao, Y., Gao, M., Mo, X., Lang, J., Wang, Z., Ma, Z., Meng, Y., Tang, B.-L., Liu, D., & He, H. (2025) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-025-05333-x · Cited by 5
Metadata
- Authors
- Lipinski, D. M.
- Affiliations
- Medical College of Wisconsin (US)
- Corresponding author
- Lipinski, Daniel M.
- ORCID
- Lipinski, Daniel M.
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer International Publishing
- Published
- 2019
- Volume
- 1185
- Pages
- 79-83
- ISSN
- 0065-2598 (ISSN-L)
- 2214-8019
- OpenAlex
- W2998320773
- Cited by
- 8
- References
- 27
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2020: 1
- FWCI
- 1.24
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Advances in experimental medicine and biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- inducible gene expression, recombinant adeno-associated virus vectors, ocular gene therapy, retinal gene therapy, inducible promoters, transgenic overexpression, retinal disease, temporal control of gene expression
- MeSH terms
- Dependovirus, Genetic Vectors, Humans, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, Transgenes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comparison of Inducible Gene Expression Platforms: Implications for Recombinant Adeno-Associated Virus (rAAV) Vector-Mediated Ocular Gene Therapy. https://app.cochat.ai/papers/10.1007/978-3-030-27378-1_13
- The paper
- Lipinski, D. M. (2019). A Comparison of Inducible Gene Expression Platforms: Implications for Recombinant Adeno-Associated Virus (rAAV) Vector-Mediated Ocular Gene Therapy. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-3-030-27378-1_13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.